Ally Bridge Group (NY) LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Ally Bridge Group (NY) LLC disclosed 13 US equity positions worth $63.0m in its Q4 2025 13F filing. The largest position was ABVX at 15.0% of the reported book, followed by SLNOEUR and ATAI BECKLEY NV. Against the Q3 2025 filing, it opened 7 new positions, added to 0 and reduced 5 among the top 13 holdings.
What did Ally Bridge Group (NY) LLC own in Q4 2025? Top 13 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 15.0% | $9.4m | 70,000 | – | new | |
| 2 | SLNOEUR SOLENO THERAPEUTICS INC | 12.3% | $7.8m | 168,029 | -44% | reduced | |
| 3 | ATAI BECKLEY NV | 11.1% | $7.0m | 1,713,105 | -25% | reduced | |
| 4 | IVA INVENTIVA SA | 11.1% | $7.0m | 1,500,000 | – | new | |
| 5 | NERV MINERVA NEUROSCIENCES INC | 10.6% | $6.7m | 1,655,500 | – | new | |
| 6 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 9.3% | $5.9m | 19,882 | – | new |
| 7 | EWTX EDGEWISE THERAPEUTICS INC | 7.7% | $4.8m | 195,000 | – | new | |
| 8 | EPRX EUPRAXIA PHARMACEUTICALS INC | 4.8% | $3.0m | 397,895 | -57% | reduced | |
| 9 | OVID OVID THERAPEUTICS INC | Healthcare | 4.6% | $2.9m | 1,785,000 | – | new |
| 10 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 4.0% | $2.5m | 457,132 | -76% | reduced |
| 11 | SLDB SOLID BIOSCIENCES INC | Healthcare | 3.7% | $2.3m | 413,625 | -25% | reduced |
| 12 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 3.1% | $2.0m | 817,939 | 0% | held |
| 13 | PROMIS NEUROSCIENCES INC | 2.7% | $1.7m | 249,339 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.